Ocrevus Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved understanding of multiple sclerosis pathology, approvals for disease-modifying therapies, expansion of neurology specialty care, increasing ms diagnosis rates, availability of biologic infusion infrastructure.

The growth in the forecast period can be attributed to growing adoption of personalized ms treatment approaches, expansion of home and outpatient infusion services, rising investments in neuroimmunology research, increasing focus on slowing disease progression, development of next-generation monoclonal antibodies. Major trends in the forecast period include increasing use of monoclonal antibody therapies for ms, rising adoption of b-cell targeted treatments, expansion of infusion center-based care models, growing focus on long-term disease modification, enhanced patient monitoring and real-world evidence collection.

The increasing prevalence of multiple sclerosis is expected to drive the growth of the Ocrevus market going forward. Multiple sclerosis (MS) is a chronic autoimmune condition that affects the central nervous system, in which the immune system mistakenly attacks the protective myelin sheath surrounding nerve fibers. The rise in multiple sclerosis cases is attributed to a combination of genetic, environmental, and lifestyle factors, including improved diagnostic capabilities, greater awareness, and changes associated with urban living and dietary habits. Ocrevus is used in the treatment of multiple sclerosis to reduce disease activity, slow disease progression, and manage symptoms by targeting and depleting CD20-positive B cells that play a key role in immune-mediated nerve damage. For instance, in May 2024, according to the MS Society UK, a UK-based non-profit organization, more than 150,000 people were living with MS in the UK as of 2024, with prevalence increasing by 15% in England, 10% in Scotland, 9% in Northern Ireland, and 8% in Wales. Therefore, the growing prevalence of multiple sclerosis is driving the Ocrevus market.

The increasing emphasis on personalized medicine is expected to propel the growth of the Ocrevus market going forward. Personalized medicine enables healthcare providers to develop tailored treatment plans and make more informed therapeutic decisions by leveraging a patient’s genetic and molecular information to better understand disease characteristics. The focus on personalized medicine is expanding due to its ability to improve treatment efficacy, minimize adverse effects, and meet the rising demand for customized healthcare solutions supported by advances in genetic testing and diagnostic technologies. This trend positively impacts Ocrevus by supporting its targeted treatment approach for multiple sclerosis, enhancing patient outcomes, and reinforcing its position as a preferred therapy. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare diseases in 2023, compared with six approvals in 2022. Therefore, the growing focus on personalized medicine is driving the growth of the Ocrevus market.

Major companies operating in the Ocrevus market are concentrating on developing innovative treatment options, including subcutaneous combination formulations, to address the rising demand for more convenient administration methods, greater treatment flexibility, and expanded access for patients with multiple sclerosis. Subcutaneous formulations combine monoclonal antibodies with absorption-enhancing agents, allowing quicker administration and reducing the treatment burden compared with traditional intravenous infusions that require longer clinic visits. For instance, in September 2024, Genentech Inc., a US-based biotechnology company, announced that the U.S. Food and Drug Administration approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of both relapsing multiple sclerosis and primary progressive multiple sclerosis. Ocrevus Zunovo is the first subcutaneous injection administered by healthcare professionals twice yearly, with each session lasting approximately 10 minutes. This approval expands treatment options for individuals living with multiple sclerosis and provides healthcare providers with greater flexibility to tailor patient care.

Major companies operating in the ocrevus market are F. Hoffmann-La Roche Ltd.

North America was the largest region in the ocrevus market in 2025. The regions covered in the ocrevus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ocrevus market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are affecting the Ocrevus market by increasing costs of imported monoclonal antibody production equipment, bioreactor components, sterile delivery systems, and cold-chain logistics services. Neurology treatment centers in North America and Europe are most impacted due to reliance on globally sourced biologics infrastructure, while Asia-Pacific faces cost pressures in expanding biologics manufacturing capacity. These tariffs contribute to higher treatment and distribution costs. However, they are also encouraging domestic biologics production, regional clinical manufacturing hubs, and investments in localized pharmaceutical supply chains.

The ocrevus market research report is one of a series of new reports that provides ocrevus market statistics, including ocrevus industry global market size, regional shares, competitors with a ocrevus market share, detailed ocrevus market segments, market trends and opportunities, and any further data you may need to thrive in the ocrevus industry. This ocrevus market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ocrevus is a prescription monoclonal antibody therapy used for the treatment of relapsing forms of multiple sclerosis (RMS), including relapsing-remitting MS, active secondary progressive MS, and primary progressive MS (PPMS). It functions by targeting and reducing CD20-positive B cells, which play a significant role in the immune-driven damage to nerve cells seen in multiple sclerosis.

The main types of indications for Ocrevus include relapsing-remitting multiple sclerosis and primary progressive multiple sclerosis. Relapsing-remitting multiple sclerosis (RRMS) is a type of multiple sclerosis marked by distinct episodes of neurological symptoms followed by phases of partial or complete recovery. It is available in liquid as well as tablet or capsule forms and can be administered through oral and injectable routes. It is utilized by hospitals, retail pharmacies, and online pharmacies.

The ocrevus market consists of sales of monoclonal antibodies, cancer therapies, infusion delivery systems and research and development tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.